Abcam plc logo
Abcam plc ABCM
report update icon

Quarterly report 2022-Q4
added 05-23-2026

Abcam plc Financial Ratios 2022-2011 | ABCM

Brief overview of Abcam plc's market valuation

This overview follows the five latest available observations from 2020 through 2022.

The current valuation set is P/S 13.66x (median 16.93x), P/B 6.8x (median 7.52x), P/CF 172.12x (median 142.11x). The multiple basket looks neutral against its history, differing from median levels by roughly -9.7%.

Capital efficiency is characterized by ROE -1.2%, ROA -0.8%, ROCE -1.2%. Current return ratios are negative, materially weakening the fundamental profile.

Overall assessment

Abcam plc's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.

Annual Financial Ratios Abcam plc

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-581.2 1213.4 369.7 - - - - - - - - -

P/S

13.7 16.9 32.1 - - - - - - - - -

EPS

-0.0 0.0 0.1 0.1 - - - - - - - -

EV (Enterprise Value)

5.18 B 5.59 B 4.71 B -25.2 M 63.1 M 54.6 M 68.4 M 35.8 M 25.7 M 29.6 M 27.6 M 12.6 M

EBITDA per Share

-0.04 0.03 0.08 0.27 - - - - - - - -

EV/EBITDA

-512.9 787.1 272.3 -0.5 - - - - - - - -

P/B

6.8 8.1 7.5 - - - - - - - - -

P/CF

172.1 84.9 142.1 - - - - - - - - -

ROE %

-1.17 0.67 2.03 11.64 - - - - - - - -

ROA %

-0.80 0.44 1.56 9.94 - - - - - - - -

ROCE %

-1.18 0.89 2.26 13.89 - - - - - - - -

Current Ratio

3.2 2.9 4.3 7.2 - - - - - - - -

All numbers in GBP currency

Quarterly Financial Ratios Abcam plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.037 - - - 0.019 - - - 0.058 - 0.06 - 0.127 - 0.217 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.04 - - - 0.03 - - - 0.08 - 0.05 - - - 0.27 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

4.03 5.20 5.20 5.20 16.84 16.17 16.17 16.17 2.03 - 2.50 - - - 11.64 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

2.74 3.55 3.55 3.55 0.44 - - - 1.56 - 1.54 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

3.56 4.75 4.75 4.75 19.24 18.35 18.35 18.35 2.26 - 1.60 - - - 14.49 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.2 - - - 2.9 - - - 4.3 - 2.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in GBP currency

Multiples are an important financial analysis tool for the company Abcam plc, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 33.25 0.78 % $ 1.93 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 13.0 0.08 % $ 5.39 B irlandaIrlanda
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 11.0 0.49 % $ 885 M usaUSA
Passage Bio Passage Bio
PASG
$ 4.5 4.39 % $ 14.4 M usaUSA
AbbVie AbbVie
ABBV
$ 261.59 0.14 % $ 463 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 14.59 0.4 % $ 4.36 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.25 1.74 % $ 278 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.78 1.92 % $ 916 M canadaCanada
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 20.15 0.52 % $ 3.39 B usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 8.09 5.2 % $ 353 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.62 0.77 % $ 264 M schweizSchweiz
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.26 0.85 % $ 645 M usaUSA
Adagene Adagene
ADAG
$ 3.2 0.28 % $ 189 M chinaChina
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.22 0.41 % $ 155 M schweizSchweiz
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 4.01 0.48 % $ 2.68 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 10.03 0.7 % $ 2.39 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 28.9 0.45 % $ 4.38 B usaUSA
Agenus Agenus
AGEN
$ 9.93 0.4 % $ 295 M usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.18 1.51 % $ 291 K usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.92 3.83 % $ 237 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 9.3 3.4 % $ 626 B britainBritain
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 1.23 13.79 % $ 73.9 M usaUSA
Alector Alector
ALEC
$ 1.85 0.27 % $ 191 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 5.63 0.18 % $ 55.7 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 40.52 1.62 % $ 6.67 B irlandaIrlanda
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 1.6 0.57 % $ 353 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 246.74 2.55 % $ 32.3 B usaUSA
Altimmune Altimmune
ALT
$ 2.86 0.34 % $ 252 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.39 2.96 % $ 74.6 M usaUSA
Amgen Amgen
AMGN
$ 421.51 0.07 % $ 227 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.81 0.09 % $ 1.21 B usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 20.14 0.22 % $ 6.31 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 50.26 0.98 % $ 1.46 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 19.66 0.1 % $ 282 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 72.65 0.04 % $ 1.46 B usaUSA
Annexon Annexon
ANNX
$ 4.23 2.42 % $ 656 M usaUSA
Annovis Bio Annovis Bio
ANVS
$ 1.27 1.92 % $ 26.1 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.75 0.16 % $ 4.9 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.82 0.54 % $ 574 K usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.63 0.11 % $ 495 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 13.69 0.36 % $ 375 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 3.42 0.88 % $ 824 M usaUSA
argenx SE argenx SE
ARGX
$ 958.91 1.33 % $ 58.8 B niderlandNiderland
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.67 2.23 % $ 133 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 26.43 0.09 % $ 3.36 B usaUSA
Artelo Biosciences Artelo Biosciences
ARTL
$ 4.04 1.11 % $ 764 K usaUSA
Arvinas Arvinas
ARVN
$ 7.74 3.13 % $ 549 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 65.45 1.21 % $ 8.75 B usaUSA